Qure.ai, which uses AI to spot abnormalities in chest and brain scans, raises $16M led by Sequoia India
More than 10.4 million people were infected with tuberculosis in 2016, according to the Center for Disease Control and Prevention, and 1.7 million of those people died …
Context & Ripple Effects
This February 2020 round is the opening move in what became one of the longer funding arcs in medical imaging AI: Sequoia India's $16M backed a startup whose qXR product reads chest X-rays for tuberculosis, a disease the CDC counted at over 10 million infections and 1.7 million deaths in 2016 alone. The bet paid forward — Qure.ai went on to raise a $40M round led by Novo Holdings and HealthQuad in 2022, then a $65M Series D led by Lightspeed and 360 ONE in 2024, by which point it claimed 3,000+ imaging sites.
What makes the early round interesting in hindsight is that the clinical case experts flagged later that year — that apps like qXR could materially change TB control in India — is exactly the use case the Sequoia money was underwriting before it was proven at scale.
First-order effects
- Qure.ai gets the capital to push its chest and brain scan algorithms from pilot deployments toward broader clinical use, with Sequoia India — where over 75% of new deals were already AI-related — as lead validator.
Second-order effects
- Hospitals and TB screening programs in India gain a funded, scaling alternative to radiologist-constrained diagnosis, pressuring incumbent imaging workflows and rival diagnostic-AI vendors to match Qure.ai's site-by-site distribution.
Third-order effects
- The trajectory from $16M to a $65M Series D across four years sketches the template now visible across health-care AI — Qventus' $105M Series D and Bunkerhill Health's $25M Series B follow the same ladder — where diagnostics and workflow automation startups compound funding against deployed-site counts rather than research milestones.
The trend: Medical imaging AI is consolidating into a small set of heavily capitalized platforms whose valuations track deployed imaging sites, with India-scale public-health use cases like TB screening as the wedge.